{"filing":{"accession_number":"0001437749-26-027835","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"mbrx20260811_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/mbrx20260811_8k.htm"},"events":[{"id":27768,"run_id":25342,"accession_number":"0001437749-26-027835","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 14, 2026 under Item 2.02. The press release (Exhibit 99.1) announces financial results including R\u0026D expenses of $5.5M, G\u0026A expenses of $2.1M, and a net loss of $7.6M for the quarter, along with unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports the company's quarterly financial performance and operational highlights including positive interim MIRACLE trial data.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29436,"accession_number":"0001437749-26-027835","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 14, 2026 under Item 2.02. The press release (Exhibit 99.1) announces financial results including R\u0026D expenses of $5.5M, G\u0026A expenses of $2.1M, and a net loss of $7.6M for the quarter, along with unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports the company's quarterly financial performance and operational highlights including positive interim MIRACLE trial data.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:32:03.874453+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29436,"accession_number":"0001437749-26-027835","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 14, 2026 under Item 2.02. The press release (Exhibit 99.1) announces financial results including R\u0026D expenses of $5.5M, G\u0026A expenses of $2.1M, and a net loss of $7.6M for the quarter, along with unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports the company's quarterly financial performance and operational highlights including positive interim MIRACLE trial data.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:32:03.874453+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-08-14"}]}